Aspirin and NSAID reactions: Diagnosis, pathophysiology, and management

Anaphylaxis and Hypersensitivity Reactions

Volumn , Issue , 2011, Pages 107-125

  White, Andrew A ^a   Laidlaw, Tanya M ^b   Woessner, Katharine ^a  

^a SCRIPPS GREEN HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

angioedema; Aspirin; aspirin exacerbated respiratory disease (AERD); asthma; chronic sinusitis; cyclooxygenase 1; cyclooxygenase 2; desensitization; ketorolac; leukotriene c4; leukotriene d4; leukotriene e4; lipoxin; nasal polyps; non IgE mediated anaphylaxis; nonsteroidal anti inflammatory drugs (NSAIDS); prostaglandin d2; prostaglandin e2; thromboxane; urticaria

Indexed keywords

EID: 84885726091     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-951-2_7     Document Type: Chapter

References (146)

1. Stevenson DD, Simon RA, Zuraw BL. Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Adkinson NF, Yunginger JW, et al., eds. Middleton's Allergy Principles and Practice, 6th edition. philadelphia, PA: Mosby; 2003:1695-1710.
2. Hedman J, Kaprio J, Poussa T, et al. prevalence of asthma, aspirin intolerance, nasal polyps and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol. 1999;28:717-722.
3. Vally H, Taylor M, Thompson PJ. The prevalence of aspirin intolerant asthma in Australian asthmatic patients. Thorax. 2002;57:569-574.
4. Kasper L, Sladek K, Duplaga M, et al. prevalence of asthma with aspirin hypersensitivity in the adult population of poland. Allergy. 2003;58:1064-1066.
5. Gomes E, Cardoso MF, Praca F, et al. Self-reported drug allergy in a general adult portuguese population. Clin Exp Allergy. 2004;34:1597-1601.
6. Kim J, Kountakis SE. The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. Ear, Nose, Throat J. 2007;86(7):396-399.
7. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000;16:432-436.
8. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin-induced asthma and its implications for clinical practice. Br Med J. 2004;328:434-437
9. Berges-Gimeno Mp, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002;89:474-478.
10. Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. J Allergy Clin Immunol. 1983:71;574-579.
11. White A, Ludington E, Mehra P, Stevenson DD, Simon RA. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol. 2006;97:688-693.
12. Hope Ap, Woessner KA, Rimon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization or patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2009;123:406-410.
13. Chen A, Bennett C. ketorolac-induced bronchospasm in an aspirin-intolerant patient. Anesth Prog. 1994;41:102-107.
14. Sitenga GL, Ing EB, Van Dellen RG, Younge BR, Leavitt JA. Asthma caused by topical application of ketorolac. Ophthalmology. 1996;103:890-892.
15. Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, Stevenson DD. prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol. 1995;96:480-485.
16. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol. 1977;60:276-284.
17. Delaney JC. The diagnosis of aspirin idiosyncrasy by analgesic challenge. Clin Allergy. 1976;6:177-181.
18. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol. 2001;108:47-51.
19. Woessner KM, Simon RA, Stevenson DD. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2004;93:339-344.
20. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in aspirin exacerbated respiratory disease. Arthritis Rheum. 2002;46:2201-2206.
21. Gyllfors BG, Overholt J, Drupka D, et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol. 2003;111:1116-1121.
22. Yoshida S, Ishizaki Y, Onuca K, et al. Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol. 2000;106:1201-1202.
23. Micheletto C, Tognella S, Guerriero M, Dal Negro R. Nasal and bronchial tolerability of rofecoxib in patients with aspirin induced asthma. Eur Ann Allergy Clinical Immunol. 2006;38:10-14.
24. Celik G, Pasaoglu G, Bavbek S, et al. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005;42:127-131.
25. Martin-Garcia C, Hinojosa M, Berges P, et al. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Invest Allergol Clin Immunol. 2003;13:20-25.
26. Szczeklik A, Nizankowska E, Bochenek G, et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy. 2001;31:219-225.
27. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108:7-13.
28. Patrignani P, Panara MR, Sciulli MG, et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and-2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol. 1997; 48:623-632.
29. Kirchner T, Argentieri DC, Barbone AG, et al. Evaluation of the Anti-inflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exper Therapeutics. 1997;282:1094-1101.
30. Prieto A, De Barrio M, Martin E, et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. J Allergy Clin Immunol. 2007;119:960-964.
31. Senna G, Bilo MB, Antonicelli L, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Eur Ann Allergy Clinl Immunol. 2004;36:215-218.
32. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma. 2004;41:67-75.
33. Bianco S, Robuschi M, Petrigni G, et al. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs. 1993;46:115-120.
34. Mascia K, Borish L, Patrie J, et al. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2005;94:652-657.
35. Young J, Frenkiel S, Tewfik MA, Mouadeb DA. Long-term outcome analysis of endoscopic sinus surgery for chronic sinusitis. Am J Rhinol. 2007;21:743-747.
36. Garrel R, Gardiner Q, khudjadze M, et al. Endoscopic surgical treatment of sinonasal polyposis-medium term outcomes (mean follow-up of 5 years). Rhinology. 2003;41:91-96.
37. Vento SI, Ertama LO, Hytonen ML, Wolff CH, Malmberg CH. Nasal polyposis: clinical course during 20 years. Ann Allergy Asthma Immunol. 2000;85:209-214.
38. Lee JH, Haselkorn T, Borish L, et al. Risk factors associated with perstent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007;132(6):1882-1889.
39. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005;116:970-975.
40. Picado C, Castillo JA, Montserrat JM, Agusti-Vidal A. Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J. 1989;2:137-139.
41. Koga T, Oshita Y, Kamimura T et al. Characterization of patients with frequent exacerbation of asthma. Respir Med. 2006;100:273-278.
42. Rachelefsky GS, Coulson A, Siegel SC, Stiehm ER. Aspirin intolerance in childhood asthma: detected by oral challenge. Pediatrics. 1975;56:443-448.
43. Vedanthan pk, Menon MM, Bell TD, Bergin D. Aspirin and tartrazine oral challenge: incidence of adverse response in chronic childhood asthma. J Allergy Clin Immunol. 1977;60:8-13.
44. Fischer TJ, Guilfoile TD, Kesarwala HH, et al. Adverse pulmonary responses to aspirin and acetaminophen in chronic childhood asthma. Pediatrics. 1983;71:313-318.
45. Towns SJ, Mellis CM. Role of acetyl salicylic acid and sodium metabisulfite in chronic childhood asthma. Pediatrics. 1984;73:631-637.
46. Debley JS, Carter ER, Gibson RL, Rosenfeld M, Redding GJ. The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocation challenge study. J Pediatr. 2005;147:233-238.
47. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2001;108:15-23.
48. Vancheri C, Mastruzzo C, Sortino MA, Crimi N. The lung as a privileged site for the beneficial actions of pGE2. Trends Immunol. 2004;25(1):40-46.
49. Sheller JR, Mitchell D, Meyrick B, Oates J, Breyer R. Ep2 receptor mediates bronchodilation by pGE2 in mice. J Appl Physiol. 2000; 88: 2214-2218.
50. Schafer D, Schmid M, Gode UC, Baenkler V. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Respir J. 1999;13:638-646.
51. Sestinini P, Armetti L, Gambaro G, et al. Inhaled pGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med. 196;572-577.
52. Roberts LJ, Sweetman BJ, Lewis RA, et al. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med. 1980;303:1400-1404.
53. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9alpha,11beta-pGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol. 2003;111(4):743-749.
54. Morris HG, Sherman NA, Shepperdson FT, Selner JC. Radioimmunoassay of thromboxane B2 in plasma of normal and asthmatic subjects. Adv Prostaglandin & Thromboxane Res. 1980;8:1759-1764.
55. Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol. 1995;96(2):148-56.
56. Antczak A, Montuschi P, Kharitonow S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med. 2002;166:301-306.
57. Ferreri NR, Howland WC, Stevenson DD, et al. Release of leukotrienes, prostaglandins and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis. 1988;137:847-854.
58. Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol. 1994;94:1046-1056.
59. Kowalski ML, Sliwinska-Kowalska M, Igarashi Y, et al. Nasal secretions in response to acetylsalicylic acid. J Allergy Clin Immunol. 1993;91:580-598.
60. Picado C, Ramis I, Rosello J, et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis. 1992;145:65-69.
61. Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm Jp. Lee TH, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143(5 pt 1):1025-1029.
62. Sladek K, Dworski R, Soja J, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med. 1994;149:940-946.
63. Daffern PJ, Muilenburg D, Hugli T. Stevenson DD. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol. 1999;104:559-564.
64. Cowburn AS, Sladek K, Soja J, et al: Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest. 1998;101:834-846.
65. Szczeklik A, Sanak M, Nizankowska E, et al. Leukotriene C4 synthase genetic polymorphism directs urinary cyteinyl-leukotriene response to aspirin challenge in asthma, Allergy. 1998;53:61-67.
66. Celik G, Bavbek S, Misirligi Z, et al. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E2 on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy. 2001;31:1615-1622.
67. Szczeklik A, Mastalerz L, Nizankowska E, et al. protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Resp Crit Care Med. 1996;152:571-576.
68. Christie PE, Spur BW, Lee TH. The effects of lipoxin A4 on airway responses in asthmatic subjects. Am Rev Respir Dis. 1992;145:1281-1284.
69. Edenius C, Kumlin M, Bjork T, Anggard A, Lindgren JA. Lipoxin formation in human nasal polyps and bronchial tissue. FEBS Lett. 1990; 272: 25-28.
70. M Sanak, BD Levy, CB Clish, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J. 2000;16:44-49.
71. Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Clin Immunol. 2008;100:420-425.
72. Macy E, Bernstein J, Castells MC, et al. Aspirin challenge and desensitization for aspirin exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98:172-174.
73. Melillo G, Balzano G, Blanco S, et al. Report of the INTERASMA Working Group on standardization of inhalation provocation tests in Aspirin-Induced Asthma: oral and inhalation provocation tests for the diagnosis of aspirin-induced asthma. Allergy. 2001;56:899-911.
74. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, et al. EAACI/GA2LEN guideline: aspirin provocation tests for the diagnosis of aspirin hypersensitivity. Allergy. 2007;62:1111-1118.
75. Mita H, Higashi N, Taniguchi M, Higashi A, Akiyama k. Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. Clin Exp Allergy. 2004;34:1262-1269.
76. Milewski M, Mastalez L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol. 1998;101:581-586.
77. Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, et al. Nasal provocation test (NpT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy. 2002;57:632-635.
78. Casadevall J, Ventura p-J, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax. 2000;55:921-924.
79. pawlowicz A, Williams WR, Davies BH. Inhalation and nasal challenge in the diagnosis of aspirin-induced asthma. Allergy. 1991;46:405-409.
80. White A, Bigby T, Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2006;97:190-195.
81. Martelli NA. Bronchial and intravenous provocation tests with indomethacin in aspirin-sensitive asthmatics. Am Rev Respir Dis. 1979;120:1073-1079.
82. Melillo E, LoSchiavo M, DeFelice A. Cross sensitivity to aspirin, noramidopyrine and naproxen in a patient with asthma detected by inhalation test with the three drugs. Allergy. 1993;48 Suppl 16:A2325.
83. Melillo G, Balzano G, Bianco S, et al. Oral and inhalation provocation tests for the diagnosis of aspirin-induced asthma. Allergy. 2001:56:899-911.
84. Nizankowska E, Bestynska-krypel A, Cmiel A, et al. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J. 2000;15:863-869.
85. Phillips GD, Foord R, Holgate ST. Inhaled lysine-aspirin as a bronchoprovocation procedure in aspirin-sensitive asthma, its repeatability, absence of a late-phase reaction, and the role of histamine. J Allergy Clin Immunol. 1989;84:232-241.
86. Dahlen B, Zetterstrom O. Comparison of bronchial and per oral provocation with aspirin in aspirin-sensitive asthmatics. Eur Respir J. 1990;3:527-534.
87. Melillo G, Padovano A, Masi C, et al. Aspirin-intolerance in asthma: detection by a new dosimeter inhalation test. Aerosol Med. 1991;4:865.
88. Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA. 2004;292:3017-3023.
89. Berges-Gimeno Mp, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111:180-186.
90. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long term outcomes. J Allergy Clin Immunol. 1996;98:751-758.
91. Berges Gimeno Mp, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2003;90:338-341.
92. Lee J Y, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2007;119:157-164.
93. Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol. 2006;118:801-804.
94. Shaker M, Lobb A, Jenkins P, et al. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2008;121:81-87.
95. Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300mg aspirin daily. Allergy. 2008;63:1228-1234.
96. Stevenson DD, Pleskow WW, Simon RA, et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol. 1984;73:500-507.
97. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106:13S-24S.
98. Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-sensitive asthmatics. Am J Resp Crit Care Med. 1998;157:1187-1194.
99. Dahlen S, Malstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double blind, placebo controlled trial. Am J Respir Crit Care Med. 2002;165:9-14.
100. Micheletto C, Tognella S, Visconti M,. Montelukast 10 mg improves nasal function and nasal response in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy. 2004;59:284-294.
101. Israel E, Cohn J, Dube L, Drazen J. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA. 1996;275:931-936.
102. Joos S, Miksch A, Szecsenyi J, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008;63:453-462.
103. Berges-Gimeno Mp, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy. 2002;32:1491-1496.
104. White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2005;95:330-335.
105. Stevenson DD, Simon RA, Mathison DA, Christiansen SC. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol. 2000;85:477-482.
106. Obase Y, Shimoda T, Tomari S, et al. Effects of pranlukast on aspirin-induced bronchoconstriction: differences in chemical mediators between aspirin-intolerant and tolerant asthmatic patients. Ann Allergy Asthma Immunol. 2001;87:74-79.
107. Lee DkC, Haggart K, Robb FM, Lipworth BJ. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J. 2004;24:226-230.
108. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993;148:1447-1451.
109. Pauls JD, Simon RA, Daffern PJ, Stevenson DD. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol. 2000;85:40-45.
110. Ogata N, Darby Y, Scadding G. Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol. 2007;121:1156-1160.
111. Patriarca G, Bellioni P, Nucera E, et al. Intranasal treatment with lysine acetylsalicylate in patients with nasal polyposis. Ann Allergy. 1991;67:588-592.
112. Nucera E, Shiavino D, Milani A, et al. Effects of lysine-acetylslicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies. Thorax. 2000;55:S75-S78.
113. Parikh AA, Scadding GK. Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope. 2005;115:1385-1390.
114. Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol. 1982;69:11-19.
115. Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B4 production following aspirin desensitization. J Allergy Clin Immunol. 1995;96:148-156.
116. Nasser SM, Patel M, Bell GS, Lee TH. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med. 1995;15:1326-1330.
117. Arm JP, Austen kF. Leukotriene receptors and aspirin sensitivity. N Engl J Med. 2002;347:1524-1526.
118. Arm JP, ÓHickey SP, Spur BW, Lee TH. Airway responsiveness to histamine and leukotriene E(4) in subjects with aspirin-induced asthma. Am Rev Respir Dis. 1989;140:148-153.
119. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Eng J Med. 2002;347:1493-1499.
120. th ed. philadelphia, pA: Mosby; 2008:1227-1239.
121. Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angioedema: a review of 554 patients. Br J Dermatol. 1969;81:588-597.
122. Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol. 1981;104:369-381.
123. Mastalerz L Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004;113:771-775.
124. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclo-oxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol. 2005;94:34-38.
125. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol. 2001;87:201-204.
126. Pacor M, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy. 2002;32:397-400.
127. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclo-oxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol. 2003;139:1577-1582.
128. Asero R. Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol. 2003;111:1095-1098.
129. Rossini R, Angiolillo DJ, Musumeci G, et al. Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiology. 2008;101:786-789.
130. Dalmau G, Gaig P, Gazquez V, Merce J. Rapid desensitization to acetylsalicylic acid in acute coronary syndrome patients with NSAID intolerance. Rev Esp Cardiol. 2009;62:224-225.
131. Silberman S, Neukirch-Stoop C, Steg pG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol. 2005;95;509-510.
132. Wong JT, Nagy CS, Krinzman SJ et al. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol. 2000;105:997-1001.
133. Grzelewska-Rzymowska I, Rozniecki J, Szmidt M. Aspirin "desensitization" in patients with aspirin-related urticaria-angioedema. Allergol Immunopathol. 1988;16:305-308.
134. Slowik SM, Slavin RG. Aspirin desensitization in a patient with aspirin sensitivity and chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2009;102:171-172.
135. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclo-oxygenase enzymes. Ann Allergy Asthma Immunol. 2001;87:1-4.
136. van der klauw MM, Stricker BH, Herings RM, et al. A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol. 1993;35:400-408.
137. Berkes EA. Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs. Clin Rev Allergy Immunol. 2003;24:137-148.
138. Van puijenbroek EpEA, Meyboom RH, Leufkens HG. Different risks for NSAID-induced anaphylaxis. Ann Pharmacother. 2002;36:24-29.
139. Strom BL, Carson JL, Schinnar R. The effect of indication on the risk of hypersensitivity reactions associated with tolmetin sodium versus other nonsteroidal anti-inflammatory drugs. J Rheumatol. 1988;15:695-699.
140. Asero R. Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. Clin Exp Allergy. 2005;35:713-716.
141. Asero R. Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. Ann Allergy Asthma Immunol. 2006;97:187-189.
142. Gagnon R, Julien M, Gold p. Selective celecoxib-associated anaphylactoid reaction. J Allergy Clin Immunol. 2003;111:1404-1405.
143. Levy MB, Fink JN. Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol. 2001;87:72-73.
144. Grob M, Pichler WJ, Wuthrich B. Anaphylaxis to celecoxib. Allergy. 2002;57:264-265.
145. Schellenberg R, Isserow SH. Anaphylactoid reaction to a cyclo-oxygenase-2 inhibitor in a patient who had a reaction to a cyclo-oxygenase-1 inhibitor. N Engl J Med. 2001;345:1856.
146. Ballou LR, Wang BWE. Nonsteroidal Anti-inflammatory Drugs. In: Firestein GF, Budd RC, et al., eds. Kelley's Textbook of Rheumatology, 8th edition. philadelphia, pA: W.B Saunders; 2008:843.